Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2019 Filed Jul 16, 2019 20:48 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,500 | $64.55 | $161,375.00 |
DisclosureSEC source: 0001209191-19-042178 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 20:45 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 409 | $81.39 | $33,288.51 |
DisclosureSEC source: 0001209191-19-042176 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,473 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 20:42 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 430 | $81.39 | $34,997.70 |
DisclosureSEC source: 0001209191-19-042173 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,207 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Tax withholdingCommon Stock | 404 | $85.28 | $34,453.12 |
DisclosureSEC source: 0001209191-19-041584 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,947 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC |
Trower PaulPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 148 | $85.28 | $12,621.44 |
DisclosureSEC source: 0001209191-19-041579 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,597 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 7,595 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:43 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 267 | $85.28 | $22,769.76 |
DisclosureSEC source: 0001209191-19-041573 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,882 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:47 UTC |
SWAIN PAULA JEVP, Human Resources
|
Tax withholdingCommon Stock | 404 | $85.28 | $34,453.12 |
DisclosureSEC source: 0001209191-19-041576 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,251 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:40 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
Tax withholdingCommon Stock | 273 | $85.28 | $23,281.44 |
DisclosureSEC source: 0001209191-19-041571 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,539 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 12,562 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:37 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 1,552 | $85.28 | $132,354.56 |
DisclosureSEC source: 0001209191-19-041568 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,596 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 139,764 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:34 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 273 | $85.28 | $23,281.44 |
DisclosureSEC source: 0001209191-19-041565 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,637 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:46 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040919 · doc4.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:46 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 417 | $85.01 | $35,449.17 |
DisclosureSEC source: 0001209191-19-040919 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,149 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:46 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040919 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,566 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:58 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040952 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:58 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Tax withholdingCommon Stock | 619 | $85.01 | $52,621.19 |
DisclosureSEC source: 0001209191-19-040952 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,351 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:58 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040952 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,970 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:35 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040898 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:35 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 417 | $85.01 | $35,449.17 |
DisclosureSEC source: 0001209191-19-040898 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,910 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:35 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040898 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,327 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 19:08 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantEmployee Stock Option (right to buy) · Derivative | 96,327 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040962 · doc4.xml · derivative · entry 5 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,327 Underlying: Common Stock · 96,327 shares Expires 2029-07-01 F5 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 19:08 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 2,410 | $85.01 | $204,874.10 |
DisclosureSEC source: 0001209191-19-040962 · doc4.xml · nonDerivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,148 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 143,104 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 19:08 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantCommon Stock | 39,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040962 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,558 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Herve Hoppenot's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:54 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,289 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040947 · doc4.xml · derivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,289 Underlying: Common Stock · 2,289 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:54 UTC |
Trower PaulPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 336 | $85.01 | $28,563.36 |
DisclosureSEC source: 0001209191-19-040947 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,745 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 7,894 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:54 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantCommon Stock | 3,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040947 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,081 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Paul Trower's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:50 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040932 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:50 UTC |
SWAIN PAULA JEVP, Human Resources
|
Tax withholdingCommon Stock | 619 | $85.01 | $52,621.19 |
DisclosureSEC source: 0001209191-19-040932 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,655 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:50 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040932 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,274 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Paula Swain's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:43 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040912 · doc4.xml · derivative · entry 3 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:43 UTC |
Pasquale Maria EEVP & General Counsel
|
Tax withholdingCommon Stock | 470 | $85.01 | $39,954.70 |
DisclosureSEC source: 0001209191-19-040912 · doc4.xml · nonDerivative · entry 2 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,304 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 15,249 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:43 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040912 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,774 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Maria Pasquale's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:39 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040906 · doc4.xml · derivative · entry 3 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:39 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
Tax withholdingCommon Stock | 417 | $85.01 | $35,449.17 |
DisclosureSEC source: 0001209191-19-040906 · doc4.xml · nonDerivative · entry 2 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,812 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 13,441 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:39 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040906 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,229 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Vijay Iyengar's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:31 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040882 · doc4.xml · derivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F3 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:31 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040882 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,639 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 13,639 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 7, 2020 23:29 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,534 | $0.00 Strike: $106.47 | $0.00 |
DisclosureSEC source: 0001209191-20-041570 · doc4.xml · derivative · entry 4 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,534 Underlying: Common Stock · 2,534 shares Expires 2030-07-01 F4 · derivative.exercise_date: Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:33 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 208 | $84.96 | $17,671.68 |
DisclosureSEC source: 0001209191-19-040315 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,115 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:39 UTC |
FOUSE JACQUALYN ADirector
|
GrantCommon Stock | 203 | $84.96 | $17,246.88 |
DisclosureSEC source: 0001209191-19-040335 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,580 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:31 UTC |
Clancy Paul JDirector
|
GrantCommon Stock | 237 | $84.96 | $20,135.52 |
DisclosureSEC source: 0001209191-19-040306 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:27 UTC |
BROOKE PAUL ADirector
|
GrantCommon Stock | 291 | $84.96 | $24,723.36 |
DisclosureSEC source: 0001209191-19-040297 · doc4.xml · nonDerivative · entry 1 BROOKE PAUL A · CIK 0001175940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,016 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:23 UTC |
BIENAIME JEAN JACQUESDirector
|
GrantCommon Stock | 195 | $84.96 | $16,567.20 |
DisclosureSEC source: 0001209191-19-040281 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,779 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:05 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector
|
GrantCommon Stock | 310 | $84.96 | $26,337.60 |
DisclosureSEC source: 0001638599-19-000640 · doc4_6167.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 29,290,843 F4 · ownership.nature: 310 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $26,338. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F7 · ownership.nature: Includes beneficial ownership of 3,376 shares previously issued pursuant to the Stock Incentive Plan in lieu of director retainer fees, 135,000 shares received previously from exercise of 135,000 stock options of the Issuer and 1,520 restricted stock units payable solely in Common Stock that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which each of the Funds may be deemed to own a portion. F8 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock of the Issuer reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 310 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:05 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector
|
GrantCommon Stock | 310 | $84.96 | $26,337.60 |
DisclosureSEC source: 0001638599-19-000640 · doc4_6167.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,827,076 F4 · ownership.nature: 310 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $26,338. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F7 · ownership.nature: Includes beneficial ownership of 3,376 shares previously issued pursuant to the Stock Incentive Plan in lieu of director retainer fees, 135,000 shares received previously from exercise of 135,000 stock options of the Issuer and 1,520 restricted stock units payable solely in Common Stock that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which each of the Funds may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 310 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:46 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 8,357 | $87.96 | $735,081.72 |
DisclosureSEC source: 0001209191-19-039000 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,805 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $87.23 - $89.01. F4 · balance_after: Includes an aggregate of 10,805 shares of common stock issuable pursuant to previously reported earned performance stock units and restricted stock units that have not vested. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 21:26 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-19-037771 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,639 Underlying: Common Stock · 2,500 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 21:26 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 2,500 | $80.00 | $200,000.00 |
DisclosureSEC source: 0001209191-19-037771 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,513 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 10,805 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 21:26 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,500 | $64.55 | $161,375.00 |
DisclosureSEC source: 0001209191-19-037771 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:41 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherCommon Stock | 220,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000602 · doc4_6150.xml · nonDerivative · entry 6 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,190 F9 · balance_after: Common Stock held directly by Julian C. Baker including 220,141 shares of Common Stock received from the in-kind pro rata distributions without consideration reported above. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:41 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherCommon Stock | 220,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000602 · doc4_6150.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,773 F8 · balance_after: Common Stock held directly by Felix J. Baker including 220,141 shares of Common Stock received from the in-kind pro rata distributions without consideration reported above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.